# US 2018/0023058 A1 · Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023058 A1
- Document ID: US20180023058A1
- Status: Published application
- Kind: A1
- Application number: 15/541,913
- Filed: 2015-01-07
- Published: 2018-01-25
- Earliest claimed: 2015-01-07
- Assignees: Frontier Bio-Drug Development Limited
- Applicants: Frontier Bio-Drug Development Limited
- Inventors: Chen-Lung Lin
- Web page: https://patentgrep.com/patent/US20180023058A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12Q 1/707: {non-A, non-B Hepatitis, excluding hepatitis D}
- G01N 33/5073: {Stem cells}
- G01N 33/5767: {non-A, non-B hepatitis}
- C12N 2502/70: Non-animal cells
- C12N 2770/24251: Methods of production or purification of viral material
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2333/186: Hepatitis C; Hepatitis NANB
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Hepatitis C virus replication at extrahepatic sites has been suggested; however, complete viral replication has only been confirmed in hepatocytes. Here we show that human adipogenic DLK-1+ stem cells (hADSC) freshly isolated from HCV-infected individuals contained viral transcripts, replication intermediates and viral antigens in vivo, and viral transcripts increased in supernatants upon prolonged ex vivo culture. Furthermore, naive hADSC isolated from HCV (−) individuals support complete replication of clinical isolates in vitro, and the infection is donor-nonspecific for cells and cross-genotypic for viruses. Viral infection/replication is mediated through CD81, LDL-R, SR-B1, EGFR, Apolipoprotein E, occludin, claudin-1, NPC1L1 and diacylglycerol acetyltransferase-1, and can be inhibited by anti-viral drugs. In addition, the physical properties of hADSC-propagated viral particles resemble clinical isolates more than JFH1/HCVcc, and viruses propagated by in vitro infected hADSC are infectious to primary human hepatocytes. Therefore, hADSC are an in vivo HCV reservoir and represent a novel venue of clinical virus-host interaction. hADSC can also be exploited as a physiologically relevant primary cell culture system to propagate clinical isolates.

## Claims

### Claim 1

A human adipose-derived stem cells (hADSCs)-based system for propagating hepatitis C virus (HCV), which comprises hADSCs, culture medium suitable for culturing hADSCs, and HCV.

### Claim 2 (depends on 1)

The system of claim 1, wherein the hADSCs are primary cells or passaged cells.

### Claim 3 (depends on 1)

The system of claim 1, wherein the HCV is derived from blood, serum, plasma or body fluid of an individual infected with HCV, or is a clinical HCV isolate.

### Claim 4 (depends on 1)

The system of claim 1, wherein the HCV is of genotype 1a, 1b, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 3e, 3f, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 5a and 6a, or any combination thereof.

### Claim 5 (depends on 1)

The system of claim 1, wherein the system supports complete replication of HCV.

### Claim 6

A method for propagating hepatitis C virus (HCV), comprising using hADSCs to propagate HCV in culture medium suitable for culturing hADSCs under a condition suitable for replication of HCV.

### Claim 7 (depends on 6)

The method of claim 6, wherein the hADSCs are primary cells or passaged cells.

### Claim 8 (depends on 6)

The method of claim 6, wherein the HCV is derived from blood, serum, plasma or body fluid of an individual infected with HCV, or is a clinical HCV isolate.

### Claim 9 (depends on 6)

The method of claim 6, wherein the HCV is of genotype 1a, 1b, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 3e, 3f, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 5a and 6a, or any combination thereof.

### Claim 10 (depends on 6)

The method of claim 6, wherein the method supports complete replication of HCV.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

A method for diagnosing an HCV infection in a subject comprising the steps of:
a) providing hADSCs,
b) incubating the hADSCs with a biological sample obtained from the subject in a culture medium suitable for culturing hADSCs,
c) culturing said hADSCs for a time sufficient for permitting HCV replication, and
d) detecting the level of HCV replication,
wherein the detection of an HCV replication is indicative that said subject is infected with HCV.

### Claim 14 (depends on 13)

The method according to claim 13 wherein said biological sample is derived from blood, serum, plasma or body fluid.

### Claim 15

A method for screening an anti-HCV compounds, comprising the steps of:
a) contacting hADSCs in a culture medium in a first container with HCV in the absence of a candidate compound;
b) determining the level of HCV in the culture medium in the first container in the absence of the candidate compound;
c) contacting hADSCs in a culture medium in a second container with HCV in the presence of the candidate compound;
d) determining the level of HCV in the culture medium in the second container in the presence of the candidate compound;
e) comparing the level of HCV in the presence of the candidate compound with the level of HCV in the absence of the candidate compound; and
f) identifying the candidate compound as an anti-HCV compound when the level of HCV in the presence of the candidate compound is lower than level of HCV in the absence of the candidate compound.

### Claim 16 (depends on 15)

The method of claim 15, wherein the level of HCV is determined by measuring the HCV titre, the level of an HCV nucleic acid, or the level of an HCV polypeptide.

### Claim 17 (depends on 15)

The method of claim 15, wherein the candidate compound is at least one selected from the group consisting of: a chemical compound, a protein, a peptide, a peptidomimetic, an antibody, a nucleic acid, an antisense nucleic acid, an shRNA, a ribozyme, and a small molecule chemical compound.

### Claim 18 (depends on 15)

The method of claim 15, wherein the HCV is at least one of the HCV genotypes selected from the group consisting of genotype 1a, 1b, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 3e, 3f, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 5a and 6a, or any combination thereof.

### Claim 19 (depends on 2)

The system of claim 2, wherein the passaged cells are passage 1-15 cells or passage 1-6 cells.

### Claim 20 (depends on 7)

The method of claim 7, wherein the passaged cells are passage 1-15 cells or passage 1-6 cells.
